ProLung
Early Detection of Lung Cancer
Key Facts
About Hawkeye Bio
Hawkeye Bio is a private, early-stage diagnostics company founded in 2020 and headquartered in Cambridge, Massachusetts, with additional operations in Los Angeles and Ireland. The company's core innovation is a graphene-based biosensor platform that detects disease-specific enzyme activity rather than just biomarker concentration, aiming for high sensitivity and cost-effectiveness in screening for cancer and inflammatory diseases. Its most advanced asset is the ProLung blood test for early lung cancer detection, which has demonstrated promising clinical performance metrics in early data. Hawkeye is positioned in the high-growth liquid biopsy market, targeting significant unmet needs in cancer screening compliance and accessibility.
View full company profileTherapeutic Areas
Other Early Detection of Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CIZ1B Biomarker Blood Test | Cizzle Biotechnology | Clinical Validation |
| LuCED® Lung Test | VisionGate | Unknown |
| Lung Cancer Detection Program | PrognomiQ | Phase 1 |
| FirstLook Lung | DELFI Diagnostics | Unknown |